Biofrontera’s (BFRI) “Buy” Rating Reiterated at Benchmark

Benchmark restated their buy rating on shares of Biofrontera (NASDAQ:BFRI) in a research report sent to investors on Friday morning,Benzinga reports. The firm currently has a $7.00 target price on the stock.

Biofrontera Price Performance

Biofrontera stock opened at $0.73 on Friday. The stock has a fifty day moving average of $1.02 and a 200-day moving average of $1.09. Biofrontera has a 52 week low of $0.61 and a 52 week high of $4.04.

About Biofrontera

Biofrontera Inc, a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection.